L 693989

has antipneumocystis activity; structure given in first source

Also Known As:

L-693,989; L-Proline, N2-(10,12-dimethyl-1-oxotetradecyl)-(4R,5R)-4,5-dihydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(4-(phosphonooxy)phenyl)-L-threonyl-threo-3-hydroxy-L-glutaminyl-3-hydroxy-, cyclic (6-1)-peptide, monosodium salt,

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Infections 08/01/1995 - "In a separate trial, aerosol L-693,989 administered 2 h before infection (5 mg/kg) delayed mortality. "
2.	Pulmonary Aspergillosis 08/01/1995 - "We have evaluated three pneumocandins, L-693,989, L-731,373, and L-733,560, in a rat model of pulmonary aspergillosis. "
3.	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 06/01/1994 - "Water-soluble pneumocandin L-693,989, a potent antipneumocystis agent in the rat model for Pneumocystis carinii pneumonia (PCP), inhibits P. "
4.	Aspergillosis 07/01/1994 - "Semisynthetic lipopeptides such as cilofungin, LY303366, L-693,989, and L-733,560 have activity in vivo against Aspergillus infections but appear to be inactive in broth dilution in vitro tests (MICs, > 128 micrograms/ml). "

Related Drugs and Biologics

1.	Aerosols
2.	Echinocandins
3.	L 733560
4.	Lipopeptides
5.	Anidulafungin
6.	cilofungin